Eicosapentaenoic acid ethyl ester
产品说明书
 |
同义名 : | 顺-二十碳五烯酸乙酯 ;EPA ethyl ester; Ethyl eicosapentaenoate; Icosapent ethyl; AMR101 |
| CAS号 : | 86227-47-6 | |
| 货号 : | A759947 | |
| 分子式 : | C22H34O2 | |
| 纯度 : | 98% contains 2000ppm alpha-tocopherol as stabilizer | |
| 分子量 : | 330.5 | |
| MDL号 : | MFCD00673476 | |
| 存储条件： |
Pure form Keep in dark place, inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(317.7 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO 无水乙醇: 50 mg/mL(151.28 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇 |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Eicosapentaenoic acid ethyl ester is an omega-3 fatty acid agent. The enhanced contractile response by phenylephrine in diabetic mice was not altered by the administration of EPA-E (10 mg/day). In addition, the direct administration of EPA-E metabolites such as EPA, docosahexaenoic acid, and docosapentaenoic acid led to vasodilation in the aortic rings of C57BL/6 J mice. Chronic EPA-E administration prevented the development of endothelial dysfunction in KKAy mice, partly via the direct action of EPA-E metabolites on the aorta[3]. Oral administration of EPA-E ameliorated skin barrier dysfunction and pruritus in AD mice. In the SC of AD mice, covalently bound Cer were markedly diminished[4]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01002118 | Cardiovascular Disease | Not Applicable | Terminated(Unable to recruit e... 展开 >>ligible subjects; no data analyzed) 收起 << | - | United States, Iowa ... 展开 >> University of Iowa Iowa City, Iowa, United States, 52242 收起 << |
| NCT00504309 | Hypertriglyceridemia | Not Applicable | Completed | - | United States, Pennsylvania ... 展开 >> Penn State University General Clinical Research Center University Park, Pennsylvania, United States, 16802 收起 << |
| NCT01056133 | Non-alcoholic Fatty Liver Dise... 展开 >>ase Non-alcoholic Steatohepatitis 收起 << | Phase 2 | Completed | - | Canada, Ontario ... 展开 >> University Health Network, Toronto General Hospital Toronto, Ontario, Canada, M5G 1Z5 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.03mL 0.61mL 0.30mL |
15.13mL 3.03mL 1.51mL |
30.26mL 6.05mL 3.03mL |
| 参考文献 |
|---|